Clinical Trials Browser

INDUSTRY × venetoclax × Plasma cell × Clear all

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03844048 2026-03-20

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Phase 3 Active not recruiting

165 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03123029 2026-01-30

Expanded Access to Venetoclax

Available

LymphoidOther hematologic neoplasmPlasma cell

Amyloidosis, Leukemia, Plasma Cell, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

250 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT03314181 2025-08-14

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

156 enrolled

Plasma cell

Multiple Myeloma, Neoplasms

NCT02899052 2025-08-05

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

Phase 2 Active not recruiting

120 enrolled

Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT03539744 2025-06-19

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Phase 3 Active not recruiting

265 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT06115135 2025-01-16

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

Phase 2 Recruiting

39 enrolled

Plasma cell

Multiple Myeloma

NCT03530683 2024-09-03

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Phase 1 Terminated

189 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Neoplasms, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Neoplasms, Plasma Cell

NCT02755597 2023-08-22

Bellini

Phase 3 Completed

291 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT01794520 2023-04-10

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

117 enrolled 29 charts

Plasma cell

Multiple Myeloma

NCT03312530 2023-02-28

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

49 enrolled 24 charts

Plasma cell

Multiple Myeloma

NCT01794507 2021-08-02

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Phase 1 Completed

66 enrolled

Plasma cell

Multiple Myeloma

NCT02265731 2021-08-02

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

Phase 1/2 Completed

38 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT03567616 2021-06-30

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 2 Terminated

8 enrolled 12 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02391480 2019-11-29

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

Phase 1 Completed

128 enrolled

BreastGenitourinaryLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Prostatic Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma

NCT03785184 2019-08-28

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma, Neoplasms

NCT02951117 2017-06-05

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment

Phase 1 Withdrawn

Plasma cell

Multiple Myeloma

Clinical Trials

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Expanded Access to Venetoclax

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma

A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Bellini

Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

Study Evaluating Venetoclax in Subjects With Hematological Malignancies

A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment